Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial


There is an emerging realization from animal models that the immune response may have both detrimental and beneficial therapeutic effects during cancer virotherapy. However, there is a dearth of clinical data on the immune response to viral agents in patients. During a recently completed phase I trial of intravenous reovirus type 3 Dearing (RT3D), heavily pretreated patients with advanced cancers received RT3D at doses escalating from 1 × 108 tissue culture infectious dose-50 (TCID50) on day 1 to 3 × 1010 TCID50 on 5 consecutive days of a 4 weekly cycle. A detailed analysis of the immune effects was conducted by collecting serial clinical samples for analysis of neutralizing anti-reoviral antibodies (NARA), peripheral blood mononuclear cells (PBMC) and cytokines. Significant increases in NARA were seen with peak endpoint titres >1/10 000 in all but one patient. The median fold increase was 250, with a range of 9–6437. PBMC subset analysis showed marked heterogeneity. At baseline, CD3+CD4+ T cells were reduced in most patients, but after RT3D therapy their numbers increased in 47.6% of patients. In contrast, most patients had high baseline CD3+CD8+ T-cell levels, with 33% showing incremental increases after therapy. In some patients, there was increased cytotoxic T-cell activation post-therapy, as shown by increased CD8+perforin/granzyme+ T-cell numbers. Most patients had high numbers of circulating CD3−CD56+ NK cells before therapy and in 28.6% this increased with treatment. Regulatory (CD3+CD4+CD25+) T cells were largely unaffected by the therapy. Combined Th1 and Th2 cytokine expression increased in 38% of patients. These data confirm that even heavily pretreated patients are capable of mounting dynamic immune responses during treatment with RT3D, although these responses are not clearly related to the administered virus dose. These data will provide the basis for future studies aiming to modulate the immune response during virotherapy.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 4
Figure 3
Figure 5


  1. Diaz RM, Galivi F, Kottke T, Wongthida P, Qiao J, Thompson J et al. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res 2007; 67: 2840–2848.

    Article  CAS  Google Scholar 

  2. Rosen L, Evans HE, Spickard A . Reovirus infections in human volunteers. Am J Hyg 1963; 77: 29–37.

    CAS  PubMed  Google Scholar 

  3. Tai JH, Williams JV, Edwards KM, Wright PF, Crowe Jr JE, Dermody TS . Prevalence of reovirus-specific antibodies in young children in Nashville, Tennessee. J Infect Dis 2005; 191: 1221–1224.

    Article  Google Scholar 

  4. Rosen L, Hovis JF, Mastrota FM, Bell JA, Huebner RJ . Observations on a newly recognized virus (Abney) of the reovirus family. Am J Hyg 1960; 71: 258–265.

    CAS  PubMed  Google Scholar 

  5. Hashiro G, Loh PC, Yau JT . The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol 1977; 54: 307–315.

    Article  CAS  Google Scholar 

  6. Coffey MC, Strong JE, Forsyth PA, Lee PW . Reovirus therapy of tumours with activated Ras pathway. Science 1998; 282: 1332–1334.

    Article  CAS  Google Scholar 

  7. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW . The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 1998; 17: 3351–3362.

    Article  CAS  Google Scholar 

  8. Hirasawa K, Nishikawa SG, Norman KL, Coffey MC, Thompson BG, Yoon CS et al. Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 2003; 63: 348–353.

    CAS  PubMed  Google Scholar 

  9. Grünewald K, Lyons J, Fröhlich A, Feichtinger H, Weger RA, Schwab G et al. High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 1989; 43: 1037–1041.

    Article  Google Scholar 

  10. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987; 327: 293–297.

    Article  CAS  Google Scholar 

  11. Lemoine NR, Mayall ES, Wyllie FS, Farr CJ, Hughes D, Padua RA et al. Activated ras oncogenes in human thyroid cancers. Cancer Res 1988; 48: 4459–4463.

    CAS  PubMed  Google Scholar 

  12. Rodenhuis S, Slebos RJ, Boot AJ, Evers SG, Mooi WJ, Wagenaar SS et al. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res 1988; 48: 5738–5741.

    CAS  PubMed  Google Scholar 

  13. Needleman SW, Kraus MH, Srivastava SK, Levine PH, Aaronson SA . High frequency of N-ras activation in acute myelogenous leukemia. Blood 1986; 67: 753–757.

    CAS  PubMed  Google Scholar 

  14. Juillard V, Villefroy P, Godfrin D, Pavirani A, Venet A, Guillet J-G . Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Eur J Immunol 1995; 25: 3467–3473.

    Article  CAS  Google Scholar 

  15. McPhee SW, Janson CG, Li C, Samulski RJ, Camp AS, Francis J et al. Immune responses to AAV in a phase I study for Canavan disease. J Gene Med 2006; 8: 577–588.

    Article  CAS  Google Scholar 

  16. Sanchez-Perez L, Gough M, Qiao J, Thanarajasingam U, Kottke T, Ahmed A et al. Synergy of adoptive T-cell therapy and intratumoral suicide gene therapy is mediated by host NK cells. Gene Therapy 2007; 14: 998–1009.

    Article  CAS  Google Scholar 

  17. Bramson JL, Hitt M, Gauldie J, Graham FL . Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Therapy 1997; 4: 1069–1076.

    Article  CAS  Google Scholar 

  18. Fujiwara T, Tanaka N, Kanazawa S, Ohtani S, Saijo Y, Nukiwa T et al. Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer. J Clin Oncol 2006; 24: 1689–1699.

    Article  CAS  Google Scholar 

  19. Hernberg M, Muhonen T, Turunen JP, Hahka-Kemppinen M, Pyrhönen S . The CD4+/CD8+ ratio as a prognostic factor in patients with metastatic melanoma receiving chemoimmunotherapy. J Clin Oncol 1996; 14: 1690–1696.

    Article  CAS  Google Scholar 

  20. Yang WQ, Lun X, Palmer CA, Wilcox ME, Muzik H, Shi ZQ et al. Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates. Clin Cancer Res 2004; 10: 8561–8576.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to K J Harrington.

Additional information

Supplementary Information accompanies the paper on Gene Therapy website (

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

White, C., Twigger, K., Vidal, L. et al. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther 15, 911–920 (2008).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


This article is cited by


Quick links